Demographic Characteristics of Individuals With AERS of Rhabdomyolysis, Proteinuria/Nephropathy, or Renal Failure (COMPOSITE AERS) Alsheikh-Ali AA et al.

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

© 2006 National Lipid Association Statin Safety: Key Conclusions and Recommendations of the NLA.

Weng TC, et al. J Clin Pharm Ther 2010;35:

CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

Background and Objective In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S)

Philip J. Barter, et al. Circulation 2011;124:

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.

Kastelein JJ, et al. Circulation 2008;117: On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.

Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

Basic Characteristics of the Study Population Identified in Pennsylvania Medicare and Pharmaceutical Assistance Contract for the Elderly, 1994–2000 Soko.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:

Shalev V, et al. Arch Intern Med 2009; 169:

Flow diagram of the systematic literature search indicating the inclusion and exclusion process of studies Liakopoulos OJ, et al. Eur Heart J 2008;29:

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:

Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Adverse events for rosuvastatin

Muscle pain with taking statin

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:

مبررات إدخال الحاسوب في رياض الأطفال

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Nat. Rev. Nephrol. doi: /nrneph

Creatinine clearance (mL/min) n All-cause mortality (%)

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

Mean eGFR among survivors after CABG surgery vs all-cause deaths

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Trial profile John A Dormandy et al. Lancet 2005;366:

Rounded incidence values (%) of renal and nonrenal events

Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Relative risk of major events with atenolol vs placebo

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

End point Fenoldopam, n (%) Dopamine, n (%) p

21twelveinteractive.com/ twitter.com/21twelveI/ facebook.com/21twelveinteractive/ linkedin.com/company/21twelve-interactive/ pinterest.com/21twelveinteractive/

Trial Selection Process

Individual Variation in Drug Responses

A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics by Tertiles of Homocysteine

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Study Identification and Selection Process

Baseline Characteristics of Study Populations

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.

Plasma biomarker concentrations between study groups.

Framework for integrating taxonomic and metabolomic data.

BETONLINEBETONLINE A·+A·+

Scoring of Coronary Artery Disease Characteristics on Coronary CT Angiograms by Using Machine Learning For prediction of all-cause mortality on the basis.

Glucose, insulin, and AGE levels during an OGC before and after RT

Spatial distribution of individual genotypes in a subpart (of size 500 grid units × 700 grid units) of the total grid after the last cycle in one replicate.

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Flow of study participants

Low/moderate intensity statins High intensity statins

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Physiological characteristics of large fastigial glycinergic neurons resemble those of large glutamatergic neurons, not small glycinergic neurons. a, Action.

QUALITY: SAFE CARE Prescription of Potentially Unsafe Medications Among Elderly Beneficiaries, by Hospital Referral Regions, 2007 Percent of elderly Medicare.

Low/moderate intensity statins High intensity statins

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Presentation transcript:

Demographic Characteristics of Individuals With AERS of Rhabdomyolysis, Proteinuria/Nephropathy, or Renal Failure (COMPOSITE AERS) Alsheikh-Ali AA et al Circulation. 2005; 111:3051

Rates of composite end point of AERs of rhabdomyolysis, proteinuria/nephropathy, or renal failure (COMPOSITE AERs) associated with various statins †P0.001 for pairwise comparison vs rosuvastatin Alsheikh-Ali AA et al Circulation. 2005; 111:3051

Percent of Statin-Associated COMPOSITE AERS (of Rhabdomyolysis, Proteinuria/Nephropathy, or Renal Failure) Listing Concomitant Use of Other Drugs That Can Potentially Interact With Statins Alsheikh-Ali AA et al Circulation. 2005; 111:3051

Rates of each category of AERs associated with various statins Alsheikh-Ali AA et al Circulation. 2005; 111:3051

Rates of each category of AERs associated with various statins during respective first postmarketing year for each statin Alsheikh-Ali AA et al Circulation. 2005; 111:3051